INOVIO Pharmaceuticals
NEWS ALERT

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Press Releases

INOVIO to Present at the Jefferies 2021 Virtual Healthcare Conference

Posted on May 25, 2021

INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors

Posted on May 17, 2021

INOVIO’s Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies

Posted on May 12, 2021

INOVIO Reports First Quarter 2021 Financial Results

Posted on May 10, 2021

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine

Posted on May 10, 2021

INOVIO to Present at Upcoming Investor Conferences in May

Posted on May 4, 2021

INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021

Posted on April 27, 2021

INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800

Posted on April 23, 2021

INOVIO’s COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern

Posted on April 15, 2021

INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel

Posted on March 15, 2021

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.